Shenzhen University General Hospital

This early-phase trial is testing a new type of CAR-T cell therapy, called CD19-CAR.p40-T, in 10 adults with B-cell lymphoma, acute lymphoblastic leukemia, or acute myeloid leukemia that has come back or not responded to treatment. Participants receive chemotherapy followed by an…

This study tests a new treatment for people with B-cell lymphoma that has come back or not responded to standard care. The treatment uses specially engineered immune cells (CAR/TRuC-T) that target two markers on cancer cells (CD19 and CD20). About 20 adults will receive chemother…

This study tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) in adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if the treatment can clear hidden cancer cells from the bone marrow and keep them away.…

This study tests a new treatment called MSLN CAR-T for people with advanced solid tumors that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to target a protein called MSLN found on tumor cells. Up to 20 adults will receive c…